GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SSSGY) » Definitions » Gross Profit

Sartorius AG (Sartorius AG) Gross Profit : $1,616 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Sartorius AG Gross Profit?

Sartorius AG's gross profit for the three months ended in Mar. 2024 was $431 Mil. Sartorius AG's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $1,616 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Sartorius AG's gross profit for the three months ended in Mar. 2024 was $431 Mil. Sartorius AG's Revenue for the three months ended in Mar. 2024 was $891 Mil. Therefore, Sartorius AG's Gross Margin % for the quarter that ended in Mar. 2024 was 48.33%.

Sartorius AG had a gross margin of 48.33% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Sartorius AG was 53.31%. The lowest was 45.10%. And the median was 50.82%.

Warning Sign:

Sartorius AG gross margin has been in long-term decline. The average rate of decline per year is -1.3%.


Sartorius AG Gross Profit Historical Data

The historical data trend for Sartorius AG's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Gross Profit Chart

Sartorius AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,045.67 1,467.63 2,077.85 2,307.31 1,708.94

Sartorius AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 486.94 440.85 383.99 361.07 430.54

Competitive Comparison of Sartorius AG's Gross Profit

For the Medical Instruments & Supplies subindustry, Sartorius AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius AG's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Gross Profit distribution charts can be found below:

* The bar in red indicates where Sartorius AG's Gross Profit falls into.



Sartorius AG Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Sartorius AG's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=3703.053 - 1994.111
=1,709

Sartorius AG's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=890.87 - 460.327
=431

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,616 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Sartorius AG's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=431 / 890.87
=48.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sartorius AG  (OTCPK:SSSGY) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sartorius AG had a gross margin of 48.33% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Sartorius AG Gross Profit Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius AG (Sartorius AG) Business Description

Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.